Exelixis Comprehensive Income 2010-2024 | EXEL

Exelixis comprehensive income for the quarter ending December 31, 2024 was $-0.001B, a 64.08% decline year-over-year.

  • Exelixis comprehensive income for 2024 was $-0.001B, a 64.08% decline from 2023.
  • Exelixis comprehensive income for 2023 was $-0.004B, a 74.18% decline from 2022.
  • Exelixis comprehensive income for 2022 was $-0.015B, a 1815.7% increase from 2021.

Exelixis Comprehensive Income 2010-2024 | EXEL

  • Exelixis comprehensive income for 2024 was $-0.001B, a 64.08% decline from 2023.
  • Exelixis comprehensive income for 2023 was $-0.004B, a 74.18% decline from 2022.
  • Exelixis comprehensive income for 2022 was $-0.015B, a 1815.7% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B
Bio-Rad Laboratories (BIO.B)$6.3B